Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Volume Rate of Change

Score

0.3

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 71 5.9 0.56% 1.18% 5.8% -3.2% 125.8%
SHORT 71 6.3 0.52% 1.06% 4.5% -6.2% -50.5%

Summary

Technical Analysis


Volume Rate of Change Volume (VROC) is an oscillator applied to volume rather than price and is calculated in the same manner as the Rate of Change (Price) indicator. VROC highlights increases in volume which normally occur at most significant market tops bottoms and breakouts.

Calculation: Volume Rate of Change (VROC):
1) ( Volume [today] - Volume [n days ago] ) / Volume [n days ago];


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Volume Rate of Change

Download
Company Close Change(%) Volume Value Signal
ECPG Encore Capital 34.61 12 1,185,057 -70 BEARISH
BCRX BioCryst Pharmaceuticals 2.74 8.3 11,180,169 -68 BEARISH
NTRA Natera 37.25 7.1 2,078,137 -51 BEARISH
PACB Pacific Biosciences 3.52 4.1 3,526,846 -32 BEARISH
SYRS Syros Pharmaceuticals 6.65 3.3 129,382 -3 BEARISH
ATRA Atara Biotherap 11.48 2.8 639,733 -100 BEARISH
EZPW Ezcorp Inc 4.79 2.4 1,002,907 -52 BEARISH
VNET 21Vianet 15.23 1.9 1,042,902 -3 BEARISH
INTL INTL FCStone Inc 45.96 1.6 113,659 -16 BEARISH
WRLD World Acceptance 81.44 1.3 60,266 -8 BEARISH